Grace Liu, MD
MOHS-Micrographic Surgery · Newport Beach, CANPI 1477564128
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,805 of the $10,267 with a category attached, or 76.0%. AbbVie accounts for 78.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $4,956 and has fallen 97.5% since, to $124 in 2025.
Across 44 payments — averaging $233.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Medtronic$847
- Merz North America, Inc.$408
- Abbott$347
- Boston Scientific$141
- Revance Therapeutics, Inc.$141
- plus $336 from 6 others
What the payments were for
- Speaking & faculty fees$7,80576%
- Travel & lodging$8829%
- Food & beverage$1,58115%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 16 | $8,048 |
| Medtronic | 2 | $847 |
| Merz North America, Inc. | 9 | $408 |
| Abbott | 2 | $347 |
| Boston Scientific | 1 | $141 |
| Revance Therapeutics, Inc. | 6 | $141 |
| Mentor Worldwide LLC | 1 | $133 |
| Portola Pharmaceuticals, LLC | 1 | $117 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $34 |
| Prugen, Inc. Pharmaceuticals | 2 | $22 |
| Galderma Laboratories, L.p. | 1 | $21 |
| Glenmark Therapeutics Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,267 in reported general payments places this provider in the 85th percentile of 144 mohs-micrographic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 18 | $1,091 |
| Ciclopirox | 26 | $990 |
| Fluticasone Propionate | 24 | $610 |
| Doxycycline Hyclate | 20 | $333 |
| ValacyclovirValacyclovir Hcl | 19 | $304 |
| Cephalexin | 24 | $111 |
| Mupirocin | 14 | $94 |
| Triamcinolone Acetonide | 14 | $93 |
| Dutasteride | 12 | $49 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Newport Beach
- Adam RotundaNewport Beach$8K
- Anne Marie McNeillNewport Beach$7K
- Hung OngNewport Beach$4K
- Gregory HendersonNewport Beach$4K
- Sarah ArronBurlingame$98K
- Daniel Zelacla Jolla$43K
- Ralph MasseySanta Monica$38K
- Michael MortazieOrange$29K
- Sumaira AasiStanford$27K
- Andrea WilleySacramento$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.